8-K: Processa Pharmaceuticals' Next-Gen Cancer Drug Shows Promise in Phase 1b Trial, Paving Way for Phase 2

Processa Pharmaceuticals successfully completed the Phase 1b safety evaluation of its Next Generation Capecitabine (NGC-Cap) for advanced cancer, demonstrating improved tolerability and preliminary efficacy compared to standard capecitabine, leading to the selection of two dosage regimens for a Phase 2 trial in breast cancer.

Summary

• Processa Pharmaceuticals has successfully finished the safety evaluation phase of its Phase 1b trial for Next Generation Capecitabine (NGC-Cap).
• NGC-Cap is designed to enhance the efficacy and safety of the commonly used chemotherapy drug capecitabine.
• The trial involved 18 patients with advanced cancer, and the results showed that NGC-Cap provided 2-10 times greater exposure to the cancer treatment metabolite 5-FU than standard capecitabine.
• NGC-Cap was generally better tolerated than the FDA-approved capecitabine, with a lower incidence of hand-foot syndrome (HFS), a common side effect.
• The incidence of HFS was only 6% in the NGC-Cap trial, compared to over 50% in patients on standard capecitabine.
• Myelosuppression, another side effect, was observed at a rate of 71% at the highest NGC-Cap dose, comparable to the 80% rate reported for capecitabine.
• Preliminary efficacy data showed positive responses in 80% of the patients who completed the evaluation at the two highest doses of NGC-Cap.
• Based on these results, two dosage regimens have been chosen for a Phase 2 trial, which will focus on advanced or metastatic breast cancer.
• The company believes that NGC-Cap has the potential to offer better efficacy and fewer side effects than currently prescribed capecitabine.

Sentiment

Score: 8

Explanation: The results are highly positive, demonstrating both improved safety and promising efficacy. The company appears to be on a good trajectory for further development and potential FDA approval. However, the small sample size and early stage of development warrant some caution.

Positives

• NGC-Cap showed a significantly lower incidence of hand-foot syndrome (HFS) compared to standard capecitabine (6% vs. over 50%).
• Preliminary efficacy data is promising, with 80% of evaluated patients showing a positive response, including one partial response and three stable diseases.
• The company has a clear path forward with a Phase 2 trial planned for advanced or metastatic breast cancer.
• The Phase 1b data, combined with FDA feedback, has allowed for a more efficient Phase 2 and 3 strategy, potentially saving time and costs.
• NGC-Cap has the potential to treat a large patient population, as capecitabine is a widely used chemotherapy drug.

Negatives

• Myelosuppression was observed in 71% of patients at the highest dose of NGC-Cap.
• Two patients dropped out of the study due to disease progression before efficacy evaluation.
• Two patients dropped out due to side effects before efficacy evaluation.

Risks

• The positive results are based on a small number of patients in a Phase 1b trial, and further studies are needed to confirm the efficacy and safety of NGC-Cap.
• The higher exposure to 5-FU with NGC-Cap could potentially lead to increased toxicity, although the initial data suggests otherwise.
• The company may face challenges in recruiting patients for the Phase 2 trial.
• Regulatory approval is not guaranteed, and the FDA may require additional data or studies before approving NGC-Cap.
• Competitors may develop similar or superior treatments, impacting the market potential of NGC-Cap.

Future Outlook

The company plans to proceed with a Phase 2 trial of NGC-Cap in advanced or metastatic breast cancer, utilizing the two dosage regimens selected from the Phase 1b data. They anticipate a more efficient development path and a higher likelihood of FDA approval based on the positive results and FDA feedback.

Management Comments

• 'We are encouraged that NGC-Cap in the Phase 1b trial was tolerated better than or similar to the existing FDA-approved capecitabine even though the exposure to NGC-Caps 5-FU cancer-treating metabolite was 2-10 times that of capecitabine,' said David Young, PharmD, Ph.D., President of Research and Development at Processa.
• 'This greater exposure suggests that NGC-Cap can distribute more 5-FU to the cancer cells, potentially forming more cancer-killing metabolites that, in our small number of patients, has shown to improve the cancer-killing effect of NGC-Cap over capecitabine.'
• 'Given the beneficial 5-FU exposure findings, the safety results, and the preliminary efficacy evaluation, we believe that NGC-Cap may be able to provide patients with a better efficacy profile along with fewer side effects than the presently prescribed capecitabine.'
• 'Assuming this is confirmed in subsequent clinical studies, this would allow us to treat more patients with an NGC-Cap optimal dose rather than having to decrease the dose or discontinue therapy because of the tolerability with approved capecitabine.'
• 'The data obtained from the Phase 1b trial together with the feedback from the FDA have allowed us to develop a Phase 2 and 3 strategy that will likely be more efficient in terms of time and cost as well as lead to a greater likelihood of FDA approval as we expand into advanced or metastatic breast cancer in Phase 2,' concluded Dr. Young.

Industry Context

This announcement positions Processa Pharmaceuticals as a potential innovator in the oncology space, particularly in improving the delivery and efficacy of existing chemotherapy drugs. The focus on reducing side effects while enhancing efficacy aligns with a broader industry trend towards more patient-centric cancer treatments.

Comparison to Industry Standards

• The 6% incidence of HFS observed with NGC-Cap is significantly lower than the >50% incidence typically seen with standard capecitabine, such as Xeloda by Roche.
• The myelosuppression rate at the highest dose of NGC-Cap (71%) is comparable to the 80% rate reported for capecitabine in its label, but the rate of more severe myelosuppression is higher for NGC-Cap (57% vs 3%).
• For the lower NGC-Cap dose of 150 mg BID, which also has a greater 5-FU exposure than capecitabine, the incidence of myelosuppression (33%) and more severe myelosuppression (0%) was lower for NGC-Cap compared to capecitabine.
• The positive response rate of 80% in the preliminary efficacy evaluation is encouraging compared to historical response rates for capecitabine in advanced cancers, although the sample size is very small.
• Other companies developing capecitabine-based therapies or prodrugs include Teva Pharmaceutical Industries Ltd. and Mylan N.V., but Processa's approach of combining it with a DPD inhibitor to enhance 5-FU exposure is unique.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if NGC-Cap is successful in further trials and gains regulatory approval.
• Employees: Continued employment and potential for growth as the company advances its pipeline.
• Patients: Potential for a more effective and better-tolerated cancer treatment option.
• Suppliers: Potential for increased demand for products and services related to NGC-Cap development.
• Creditors: Potential for increased confidence in the company's financial stability and ability to repay debts.

Next Steps

• Initiate a Phase 2 trial of NGC-Cap in advanced or metastatic breast cancer.
• Further analyze the data from the Phase 1b trial.
• Continue to engage with the FDA on the development plan for NGC-Cap.
• Potentially evaluate NGC-Cap in other cancer types in the future.

Key Dates

Keywords

Next Generation Capecitabine, NGC-Cap, PCS6422, capecitabine, 5-FU, cancer, chemotherapy, Phase 1b, Phase 2, clinical trial, safety, efficacy, tolerability, hand-foot syndrome, myelosuppression, advanced cancer, metastatic breast cancer, FDA, Processa Pharmaceuticals